Business Context and Reporting Period
This is ChromaDex Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2024. The filing describes a global bioscience company focused on healthy aging. Its business includes Tru Niagen consumer products, Niagen ingredients, and analytical reference standards and services. The request identifies Niagen Bioscience, Inc., but the filing itself names ChromaDex Corporation (Nasdaq: CDXC) as the registrant.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Net sales | $22.2 million | $22.6 million; down 2% |
| Gross profit / margin | $13.5 million / 60.7% | $13.5 million / 59.9% |
| Operating expenses | $14.2 million | $15.5 million |
| Operating loss | $0.7 million | $2.0 million |
| Interest income, net | $0.2 million | $0.1 million |
| Net loss / loss per share | $0.5 million / $0.01 | $1.9 million / $0.03 |
| Cash from operating activities | $0.3 million | $2.8 million |
| Cash and cash equivalents | $27.6 million, including $27.4 million unrestricted | $27.3 million at Dec. 31, 2023 |
| Debt and liquidity | No outstanding line-of-credit borrowings; current liabilities $19.5 million | Lease obligations remain; see below |
At March 31, total assets were $54.1 million, total liabilities $25.1 million, and stockholders’ equity $29.0 million. Operating and finance lease liabilities totaled approximately $3.2 million. Inventory was $12.5 million. The company reported $12.5 million of inventory purchase commitments and $3.6 million of future minimum lease payments.
Material Changes Versus the Prior Comparable Period
- Sales declined by $0.4 million. Consumer Products sales fell 2% to $17.4 million; Ingredients sales were down 1% to $4.1 million; Analytical Reference Standards and Services sales fell 11% to $0.7 million.
- Tru Niagen consumer sales decreased $0.3 million: lower A.S. Watson sales, largely attributed to timing, and modestly lower distributor sales were partly offset by $0.6 million growth in e-commerce.
- Gross profit was nearly flat, while gross margin improved to 60.7% from 59.9%.
- Operating expenses declined $1.3 million. Lower sales and marketing and general and administrative costs more than offset a $0.9 million increase in R&D spending for strategic initiatives supporting future launches.
- Net loss narrowed by $1.4 million. Operating cash flow fell by $2.5 million, primarily reflecting changes in accounts payable and smaller inventory and prepaid-asset cash-flow benefits.
Outlook, Risks, Contingencies, and Unusual Items
- Liquidity outlook: Management says unrestricted cash and expected cash generation from sales should cover obligations for at least the next 12 months. However, management identified recurring operating losses and a history of negative operating cash flow as conditions requiring assessment; it also says it may seek additional capital within the next 12 months for plans beyond that period or longer-term objectives.
- Spending: Management expects fiscal 2024 sales and marketing spending to increase, with efficiencies similar to 2023. R&D expense may fluctuate with project, trial, and staffing timing.
- Customer concentration: A.S. Watson, a related party, represented 13.4% of Q1 sales. Three customers accounted for approximately 80% of receivables at quarter-end, including A.S. Watson at 41.6%; the company cites purchase timing but warns delayed or missed payments could affect cash flow and results.
- Litigation: In the Elysium patent case, the court granted Elysium’s request for attorneys’ fees and costs on March 25, 2024. The company intends to appeal and says a loss is reasonably possible; if unsuccessful, the amount sought, including estimated post-judgment interest, is approximately $9.8 million. The amount may change as the fee process proceeds. The separate California action remains subject to briefing and a scheduled hearing in August 2024. The SDNY settlement was affirmed on appeal in 2023.
- Other matters: The company describes a $1.6 million licensor claim over sublicense fees, which it disputes and does not expect to be material. It also says it does not expect the FDA/FTC warning-letter matter concerning COVID-related statements to be material. The IRS selected the company’s 2021 federal return for examination.
- Business risks: The filing highlights continued losses, possible financing needs and dilution, dependence on Tru Niagen and a single NR supplier, customer concentration, competition and marketing effectiveness, regulatory and product-claim risks, intellectual-property challenges, litigation, and risks associated with the China joint venture. Blue Hat registration required for the venture’s commercialization remains uncertain.
Most Important Facts for Investors to Verify
- Confirm the filing issuer: this 10-Q is for ChromaDex Corporation, not an issuer named Niagen Bioscience, Inc.
- Track consumer-product and e-commerce sales, A.S. Watson orders, and collection of concentrated receivables.
- Monitor operating cash flow and cash use against management’s liquidity outlook, purchase commitments, and any financing plans.
- Follow the Elysium fee-and-cost determination and appeal; the filing cites approximately $9.8 million of potential exposure if the company is unsuccessful.
- Assess whether higher R&D and planned marketing spending translate into sales growth and sustained operating improvement.